Transplantation with GXHPC1 for Liver Cirrhosis: Phase 1 Trial.

Clicks: 383
ID: 65472
2019
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Emerging

Ranked #7 of 37 articles by views in cell transplantation

Most read Least read

Bar heights use a square-root scale.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
Currently, the only effective therapy for cirrhosis of the liver is liver transplantation. However, finding a compatible liver is difficult due to the low supply of healthy livers and the ever-increasing demand. However, stem-cell therapy may offer a solution for liver cirrhosis; for example, GXHPC1 therapy preparation contains adipose-derived mesenchymal stem cells (AD-MSCs) and was developed for the treatment of liver cirrhosis. In our previous report, animal studies suggested that treatment of a diseased liver via GXHPC1 transplantation can abrogate liver fibrosis and facilitate recovery of liver function. In our current human trial, patients with liver cirrhosis were included. Their adipose tissue was harvested from the subcutaneous fat of the abdominal wall during surgery. AD-MSCs were cultured and suspended at a concentration of 100 million cells in 1 ml of physiological saline (i.e., GXHPC1). This human study passed the Taiwan Food and Drug Administration IND inspection and received Phase I clinical trial permission. The trial was conducted with six patients with liver cirrhosis to demonstrate the safety and efficacy of administering GXHPC1. Intrahepatic injection of GXHPC1 did not cause any safety issues in the analysis of adverse drug reactions and suspected unexpected serious adverse reactions, and showed a tendency for improvement of liver function, METAVIR score, Child-Pugh score, MELD score, and quality of life for patients with liver cirrhosis.
Reference Key
huang2019transplantationcell Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Huang, Ko-Chang;Chuang, Ming-Hsi;Lin, Zung-Sheng;Lin, Yi-Chun;Chen, Chun-Hung;Chang, Chao-Liang;Huang, Pi-Chun;Syu, Wan-Sin;Chiou, Tzyy-Wen;Hong, Zih-Han;Tsai, Yu-Chen;Harn, Horng-Jyh;Lin, Po-Cheng;Lin, Shinn-Zong;
Journal cell transplantation
Year 2019
DOI
10.1177/0963689719884885
URL
Keywords
liver cirrhosis adipose-derived mesenchymal stem cells intrahepatic injection stem-cell therapy

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.